Pediatr. praxi. 2008;9(4):216-221

Systemic connective tissue diseases in childhood

doc. MUDr. Pavla Doležalová CSc
Klinika dětského a dorostového lékařství 1. LF UK a VFN, Praha

Systemic connective tissue diseases are characterised by chronic inflammation and variable clinical manifestations. Despite their rarity in childhood their health impact may be serious. Timely diagnosis and early appropriate therapy are important favourable prognostic factors. Systemic lupus erythematosus (SLE) and inflammatory myopathies, namely juvenile dermatomyositis, are main representatives. SLE is a typical autoimmune multisystem disease where glomerulonephritis and neuropsychiatric lupus belong to the most serious manifestations. At disease onset fevers, fatigue, photosensitive rash and arthritis together with high sedimentation rate and cytopenia are most common. Proximal skeletal muscles and skin are the main target for chronic inflammation and often prominent vasculopathy in juvenile dermatomyositis. Progression of muscle weakness may cause respiratory insuficiency. Therapy principles are further discussed.

Keywords: Key words: systemic lupus erythematosus, juvenile dermatomyositis, clinical manifestations, therapy.

Published: November 1, 2008  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Doležalová P. Systemic connective tissue diseases in childhood. Pediatr. praxi. 2008;9(4):216-221.
Download citation

References

  1. Al-Abbad A, Cabral DA, Sanatani S et al. Echocardiography and pulmonary function testing in childhood onset systemic lupus erythematosus. Lupus 2001; 10: 32-37. Go to original source... Go to PubMed...
  2. Bohan A, Peter JB. Polymyositis and dermatomyositis. N Engl J Med 1975, 292: 344. Go to original source... Go to PubMed...
  3. Buyon JP, Hieber R, Copel J et al. Autoimmune-associated congenital heart block: demographics, mortality, morbidity and recurrence rates obtained from a national neonatal lupus registry. J Am Coll Cardiol 1998; 31: 1658-1666. Go to original source... Go to PubMed...
  4. Cassidy J, Petty R. Systemic lupus erythematosus. In: Textbook of pediatric rheumatology, 4th Ed, WB Saunders 2001, pp.396-449.
  5. Cassidy JT, Petty RE. Juvenile dermatomyositis. In: Textbook of pediatric rheumatology, 3rd Ed, W.B.Saunders Company, 1995: 323-364.
  6. Lovell DJ, Lindsley CB, Rennebohm RM et al in cooperation with the juvenile dermatomyositis disease activity collaborative study group: Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies II. The childhood myositis assessment scale (CMAS): A quantitative tool for the evaluation of muscle function. Arthritis Rheum 1999, Oct: 42(10): 2213-2219. Go to original source...
  7. Nadorra RL, Landing BH. Pulmonary lesions in childhood onset systemic lupus erythematosus: analysis of 26 cases, and summary of literature. Pediatric Pathology 1987; 7: 1-18. Go to original source... Go to PubMed...
  8. Pachman LM, Hayford JR et al. Juvenile dermatomyositis at diagnosis: Clinical characteristics of 79 children. J Rheumatol 1998: 25: 1198-1204. Go to PubMed...
  9. Reimers CD, Finkenstaedt MF. Muscle imaging in inflammatory myopathies. Curr Op Rheumatol 1997, 4: 475-485. Go to original source... Go to PubMed...
  10. Rider LG, Miller FW. Classification and treatment of the juvenile idiopathic myopathies. Rheum Dis Clin North Am 1997, 23, 23: 619-653. Go to original source... Go to PubMed...
  11. Silverman E. Systemic lupus erythematosus in children. In: Maddison PJ, Isenberg DA, Woo P, Glass DN. Oxford textbook of rheumatology, 2nd Ed, Oxford University Press 1998.
  12. Silverman ED. Neonatal lupus erythematosus. In: Textbook of pediatric rheumatology. Cassidy JT, Petty R (Ed), 2001: 450-458.
  13. Targoff IN, Miller FW et al. Classification criteria for the idiopathic inflammatory myopathies. Curr Op Rheumatol 1997, 9: 527-535. Go to original source... Go to PubMed...




Pediatrics for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.